Wednesday, February 27, 2019

Insilico to present at the Bio Asia International Conference

Wednesday, February 27, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the BIO Asia International Conference on March 6, 2019. 
Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in making the hunt for new pharmaceuticals quicker and more effective. The presentation will focus on how Artificial Intelligence demonstrates the potential to lower costs of R&D in pharmaceutical industry, helps to target patient populations more effectively, improves efficiency, and ultimately, brings new medicines to market more quickly. 
"We feel privileged to present our work at the Bio Asia 2019 and elaborate on the topic of AI technology, data challenges and its incorporation in the business operations. The topic of AI for Drug Discovery is picking up rapidly, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area," says Dr. Jimmy Yen-Chu Lin, Chief Scientific Officer of Insilico Taiwan. 
The Annual BIO Asia is an exclusive, senior-level executives forum that brings together U.S. and European drug development companies with Asian state-of-art biotech and pharmaceutical companies together in one place at one time. 
###
For further information, images or interviews, please contact:
Contact: Artur Katurin 
artur@insilico.com 
Website: http://insilico.com/ 
BioAsia Official Website: 
https://www.bio.org/events/bio-asia-international-conference
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets, published on several seminal peer-reviewed papers. The concept was further extendedand augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.
In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
Posted by at No comments:

Tuesday, February 26, 2019

Insilico to present at the WuXi Healthcare Forum 2019

Tuesday, February 26, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in Artificial Intelligence for Aging Research and Productive Longevity at the WuXi Healthcare Forum 2019 in the section titled "The new wave: Anti-Aging" in Shanghai, on March 5.
Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in studying the biology of aging on many levels. The discussion will focus on the new frontiers in the biology of aging and the future of longevity science. Another major point of discussion is how technology and industry collaborations can drive successful outcomes in longevity science.
"We are happy to present our latest research at the WuXi AppTec HealthCare Forum, which gathers the leading longevity scientists and investors. The topic of AI for Aging research and Productive longevity is rapidly gaining popularity, and we are happy to be at the leading edge of this research and one of the innovation drivers in the area", says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
"We at AAIH commend WuXi for recognizing the growing importance of artificial intelligence in improving healthcare for the global community as China has become a key player in the development of new, cutting-edge medical therapies. We are also very pleased that AAIH board director Dr. Alex Zhavoronkov of member company Insilico Medicine will have the opportunity to speak directly to the Wuxi Forum audience about the future benefits and issues associated with AI in healthcare", said Annastasiah Mudiwa Mhaka, PhD., President of AAIH.
WuXi Healthcare Forum 2019 provides unparalleled access to the industry's most respected movers and shakers - delivered through two days of visionary keynotes, country-specific tracks, 200 intimate CEO roundtables, private 1-1 coaching, and a world of collaborative opportunities. The event will take place on March 5-6 in Shanghai, one of the most dynamic cities in the world, full of spirit, innovation, and cultural splendor. 
###
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging researchincluding the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field. 
For further information, images or interviews, please contact:
Contact: Klug Gehilfe 
ai@pharma.ai
Conference Official Website : 
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Posted by at No comments:

Thursday, February 7, 2019

Insilico to contribute to Oxford CDT research and educational program in AI

Thursday, February 7, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, announces its partnership with a new Centre for Doctoral Training (CDT) at the University of Oxford, supported by EPSRC (The Engineering and Physical Sciences Research Council). 
The goal of the centre is to provide the next generation of doctoral level students with full support, to be able to combat research and innovation challenges across the engineering and physical sciences landscape. The Centre will be located within the Big Data Institute, and will play a leading role in training of health data scientists. The students will be able to complete their doctoral research under the guidance of an academic supervisor and work with a wide range of partner organisations, including Insilico Medicine.
"Insilico Medicine is one of the first AI companies to combine the expertise in artificial intelligence applied to the cutting-edge medicinal chemistry and target identification. Our set of software tools and AI libraries, deep domain expertise in target identification and medicinal chemistry, and focus on aging and age-related diseases will contribute to the educational process of the Centre for Doctoral Training. It is a wonderful initiative that makes the UK more attractive for companies like ours", - said Alex Zhavoronkov, Ph.D., founder, and CEO of Insilico Medicine, Inc.
"Thanks to the EPSRC and the BDI, we are able to deliver research training at the heart of the University's medical campus, producing the data scientists we need to help transform health research and healthcare delivery", - said Jim Davies,the Director of the CDT
The Centre is one of 75 announced on Monday at the London Stock Exchange by UK Research and Innovation. 
###
For further information, images or interviews, please contact:
Insilico Medicine Contact: Klug Gehilfe ai@pharma.ai
CDT Contact:
About BDI
The Big Data Institute is located in the Li Ka Shing Centre for Health Informatics and Discovery at the University of Oxford. It is an interdisciplinary research centre that focuses on the analysis of large, complex data sets for research into the causes, consequences, prevention and treatment of disease. Research is conducted in areas such as genomics, population health, infectious disease surveillance and the development of new analytic methods. The Big Data Institute is supported by funding from the Medical Research Council, the UK Research Partnership Investment Fund, the National Institute for Health Research Oxford Biomedical Research Centre, and philanthropic donations from the Li Ka Shing and Robertson Foundations. 
Further details are available at http://www.bdi.ox.ac.uk
About EPSRC 
The Engineering and Physical Sciences Research Council (EPSRC) is the main funding body for engineering and physical sciences research in the UK. By investing in research and postgraduate training, we are building the knowledge and skills base needed to address the scientific and technological challenges facing the nation.
EPSRC is part of UK Research and Innovation, a new body which works in partnership with universities, research organisations, businesses, charities, and government to create the best possible environment for research and innovation to flourish. We aim to maximise the contribution of each of our component parts, working individually and collectively. We work with our many partners to benefit everyone through knowledge, talent and ideas.
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
Posted by at No comments:

Monday, February 4, 2019

Longevity Vision Fund launches to support breakthrough innovation increasing human longevity

Longevity Vision Fund comes out of stealth during the Longevity Leaders forum in London
Monday, February 4th, London, UK - Recent breakthroughs in diagnostics and therapeutics of age-related diseases and aging itself lead to the emergence of the longevity biotechnology industry with a number of credible companies and exponential business models. To accelerate this emerging trend a team of professional investors and biotechnology entrepreneurs created the Longevity Vision Fund, a new venture capital fund focused on early-stage technologies and life-science businesses. The Fund seeks to invest in companies that provide products, services, and technologies aimed to extend the period of healthy human life.

Adding 20 to 30 healthy years on a person's life is likely to be the largest market opportunity on Earth. The convergence of Genome Sequencing, AI & Cellular Medicine will enable breakthroughs that will make 100 years old the new 60. I'm proud through our Bold Capital partnership to support Sergey Young and the Longevity Vision Fund", - said Dr. Peter H. Diamandis.
"The Fund's mission is to lead the breakthrough in human longevity and to extend human lifespan worldwide allowing people to live longer, healthier lives", - said Sergey Young, the Founder of Longevity Vision Fund.
Sergey Young is a visionary and investor with 20 years of experience in the field of human longevity and venture capital investing. Sergey is also development sponsor of Longevity XPRIZE and Innovation Board member at XPRIZE Foundation. Sergey is a Longevity Partner of Bold Capital Partners, and early-stage venture fund partnered with Singularity University and Peter Diamandis. Longevity Vision Fund team will be advised by leading life science experts and prominent venture investors.
The Fund's goal is to support companies worldwide focused on translating groundbreaking innovation into the next generation of therapeutics increasing human longevity as well as complementary IT products, services, and infrastructure to accelerate innovation in life sciences.
The Fund is Delaware based and has a size of $100m. The Fund cooperates with Bold Capital Partners - the investment vehicle of Peter H. Diamandis. 
###
About Longevity Vision Fund:
Longevity Vision Fund, a new venture capital fund focused on early-stage technologies and life-science businesses. The Fund seeks to invest in companies that provide products, services, and technologies aimed to extend the period of healthy human life. 
Contacts
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
Posted by at No comments:

Insilico Medicine to present at the 2nd Annual Drug Discovery Virtual Conference by LabRoots

Friday, February 1, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the 2nd Annual Drug Discovery Virtual Conference by LabRoots on February 27, 2019. 
Aging is a complex process that has been observed in all biological systems at every level of organisation. Some anti-ageing interventions have demonstrated life-extending effects in model organisms. Although very good progress has been made in the area, the translation of these interventions in human clinical practice remains limited due to the absence of comprehensive ageing biomarkers. Recent studies suggest that a set of biomarkers, rather than any individual biomarker, constitute the most effective means of assessing the health status.
The presentation will cover the development of comprehensive and robust biomarkers of ageing using deep learning and blood biochemistry, transcriptomics, and even imaging data, to be able to track the effectiveness of the various interventions we are developing.
"We are happy to present our work at the Labroots Virtual Conference. The topic of Biomarkers of Aging is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area", says Alex Zhavoronkov, Ph.D., Founder, and CEO of Insilico Medicine, Inc.
"This year's event is anticipated to bring in 16,000 registrants from around the world to participate in the conversations around Drug Discovery. We are thrilled to have Insilico Medicine join LabRoots for this event to discuss the latest in research and technologies of Aging Biomarkers, and aiding LabRoots in creating quality, educational resources to a global scientific audience, free of cost." says Tracy Salcido, Vice President of LabRoots, Inc. 
LabRoots is the leading scientific social networking website, offering top scientific trending news and premier educational virtual events and webinars. Offering more articles and webcasts that explore the latest discoveries in the world of science, LabRoots users can stay atop their field by gaining continuing education credits from a wide range of topics through their participation in the webinars and virtual events.
The event will go live on the 27th of February 2019, opens: 6:00 AM PST.
###
Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field. 
For further information, images or interviews, please contact:
Contact: Polina Firsanova 
ai@pharma.ai
About Insilico Medicine, Inc
Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com
Posted by at No comments:
Subscribe to: Posts (Atom)